Sphera Funds Management LTD. bought a new stake in Regeneron (NASDAQ:REGN) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 41,500 shares of the biopharmaceutical company’s stock, valued at approximately $14,291,000. Regeneron makes up approximately 2.2% of Sphera Funds Management LTD.’s holdings, making the stock its 10th biggest holding.
Several other large investors have also made changes to their positions in REGN. Steward Partners Investment Advisory LLC increased its stake in shares of Regeneron by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 307 shares in the last quarter. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Regeneron in the fourth quarter valued at $152,000. Advisory Services Network LLC increased its stake in shares of Regeneron by 147.0% in the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 266 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Regeneron in the fourth quarter valued at $204,000. Finally, AE Wealth Management LLC acquired a new stake in shares of Regeneron in the fourth quarter valued at $206,000. Institutional investors own 66.38% of the company’s stock.
A number of analysts have recently weighed in on REGN shares. JPMorgan Chase & Co. raised their target price on Regeneron from $455.00 to $457.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. BidaskClub upgraded Regeneron from a “strong sell” rating to a “sell” rating in a research note on Friday, January 26th. Jefferies Group restated a “hold” rating and issued a $421.00 target price on shares of Regeneron in a research note on Friday, February 2nd. Zacks Investment Research lowered Regeneron from a “hold” rating to a “sell” rating in a research note on Monday, February 5th. Finally, Canaccord Genuity restated a “buy” rating and issued a $522.00 target price on shares of Regeneron in a research note on Wednesday, February 7th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $426.88.
Regeneron opened at $295.31 on Thursday, Marketbeat.com reports. Regeneron has a fifty-two week low of $281.89 and a fifty-two week high of $543.55. The company has a current ratio of 3.59, a quick ratio of 2.94 and a debt-to-equity ratio of 0.11. The stock has a market cap of $31.74 billion, a PE ratio of 22.02, a price-to-earnings-growth ratio of 1.06 and a beta of 1.44.
Regeneron (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported $4.67 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $5.08 by ($0.41). Regeneron had a net margin of 23.54% and a return on equity of 29.92%. The business had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter last year, the firm earned $2.92 EPS. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. equities analysts expect that Regeneron will post 17.2 EPS for the current fiscal year.
In other Regeneron news, Director Joseph L. Goldstein sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $350.02, for a total value of $700,040.00. Following the sale, the director now owns 14,000 shares in the company, valued at approximately $4,900,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director George L. Sing sold 7,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $285.29, for a total value of $1,997,030.00. Following the completion of the sale, the director now owns 127,772 shares in the company, valued at approximately $36,452,073.88. The disclosure for this sale can be found here. Insiders have sold a total of 11,000 shares of company stock worth $3,377,070 in the last quarter. 12.42% of the stock is currently owned by company insiders.
Regeneron Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron (NASDAQ:REGN).
Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.